Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2025.Mar.28

News

GlycOBI® Advances Bispecific and Dual Payload ADC Development
OBI Demonstrates Innovations at the Novel Conjugates Summit in Boston

2025.Mar.26

News

OBI Wins " Most Promising Immunotherapy Pipeline" Award
Showcasing TROP2 ADC Research at Biologics World Taiwan

2025.Mar.18

News

New Chairman of OBIGEN Pharma: OBI Pharma CEO Heidi Wang Takes Over

Read More

2025.Apr.01

Announcement

OBI has submitted the IND application of a Phase I/II human clinical trial for OBI-902 TROP2 ADC to the US FDA

2025.Mar.20

Announcement

Announcement on behalf of OBIGEN that it has achieved the objectives of interim analysis for Phase 2 clinical trial of OBI-858

2025.Mar.18

Announcement

Announcement on behalf of OBIGEN that BOD resolved to apply for public offering and listing in the TPEx Emerging Stock Board

2023 Annual Report

Learn how we created value in 2023 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2024 Investors' Meeting - Innovation and Optimism

Download PDFAnnual Report

Read More

2024 Annual Shareholders’ Meeting

  • 2024.Jun.17 at 09:00 AM
  • Masterlink Securities Education and Training Center

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact